Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent UpdatesPRNewsWire • 05/13/21
Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference CallPRNewsWire • 05/06/21
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseZacks Investment Research • 05/06/21
Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker StudyBenzinga • 05/03/21
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 05/03/21
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 04/15/21
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferencePRNewsWire • 04/07/21
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent UpdatesPRNewsWire • 03/09/21
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences ConferencePRNewsWire • 03/05/21
Will Regulus (RGLS) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 03/04/21
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 02/10/21
Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock?Zacks Investment Research • 12/09/20
Regulus Therapeutics Announces Closing of $19.4 Million Private Placement of EquityPRNewsWire • 12/08/20
Regulus Therapeutics Reports Third Quarter 2020 Financial Results and Recent UpdatesPRNewsWire • 11/05/20
Regulus (RGLS) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 11/03/20
Regulus Therapeutics Announces Achievement of Interim Enrollment Milestone Under Collaboration with SanofiPRNewsWire • 11/02/20
Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)PRNewsWire • 10/15/20
Regulus Therapeutics Announces Receipt of $5 Million Milestone and Material Payments from SanofiPRNewsWire • 10/13/20
Regulus Therapeutics to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment ConferencePRNewsWire • 09/11/20